Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.40 |
| ▸ | FCER2 | P06734 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361625 | 0.91 | MDM2 (0.53) | LRRK2MDM2RETNTRK1SYK | |
| SCHEMBL5373328 | 0.88 | LRRK2 (0.52) | LRRK2MDM2MAPTRETNTRK1 | |
| SCHEMBL5363813 | 0.86 | PLK4 (0.47) | LRRK2ERN1RET | |
| SCHEMBL7138221 | 0.84 | LRRK2 (0.43) | LRRK2MDM2ERN1ALDH1A1MAPT | |
| SCHEMBL5365128 | 0.84 | LRRK2 (0.51) | LRRK2MDM2ERN1RET | |
| SCHEMBL5361653 | 0.81 | NTRK1 (0.63) | LRRK2MDM2ALDH1A1MAPTRET | |
| SCHEMBL5367921 | 0.81 | NOX4 (0.49) | ERN1ALDH1A1MAPTRET | |
| SCHEMBL5369354 | 0.80 | MAP3K7 (0.54) | LRRK2MDM2MAPTRETNTRK1 | |
| SCHEMBL5369742 | 0.80 | MAP3K7 (0.45) | LRRK2MDM2MAPTRETNTRK1 | |
| SCHEMBL5365871 | 0.80 | PTPN1 (0.49) | LRRK2MDM2RETPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | LRRK2 289/4885MDM2 888/4885ERN1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.